| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| J Roemmler, B Steffin, B Gutt, C Sievers, M Bidlingmaier, J Schopoh. The effect of acute application of pegvisomant alone and in combination with octreotide on endogenous GH levels during a 6-h test in patients with acromegaly on constant pegvisomant treatment. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 19. issue 3. 2009-08-13. PMID:19109045. |
co-treatment with somatostatin analogues and growth hormone receptor antagonists in acromegaly might be a new treatment option abolishing the negative effects of monotherapy. |
2009-08-13 |
2023-08-12 |
Not clear |
| Andrea Giustina, Stefania Bonadonna, Giovanna Bugari, Annamaria Colao, Renato Cozzi, Salvatore Cannavo, Laura de Marinis, Ettore Degli Uberti, Fausto Bogazzi, Gherardo Mazziotti, Francesco Minuto, Marcella Montini, Ezio Ghig. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. European journal of endocrinology. vol 161. issue 2. 2009-08-12. PMID:19465485. |
high-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. |
2009-08-12 |
2023-08-12 |
Not clear |
| Andrea Giustina, Stefania Bonadonna, Giovanna Bugari, Annamaria Colao, Renato Cozzi, Salvatore Cannavo, Laura de Marinis, Ettore Degli Uberti, Fausto Bogazzi, Gherardo Mazziotti, Francesco Minuto, Marcella Montini, Ezio Ghig. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. European journal of endocrinology. vol 161. issue 2. 2009-08-12. PMID:19465485. |
in acromegaly, 25-50% of patients respond inadequately to conventional long-acting somatostatin analogue (ssa) therapy. |
2009-08-12 |
2023-08-12 |
Not clear |
| Magdalene Andries, Dorte Glintborg, Annette Kvistborg, Claus Hagen, Marianne Anderse. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clinical endocrinology. vol 68. issue 3. 2009-07-30. PMID:17941902. |
somatostatin analogues have been used successfully for the treatment of acromegaly but no randomized studies have compared the effects of lanreotide autogel (lan) and octreotide acetate long-acting repeatable (oct). |
2009-07-30 |
2023-08-12 |
Not clear |
| Stine L Fougner, Olivera Casar Borota, Jens Petter Berg, John K Hald, Jon Ramm-Pettersen, Jens Bollersle. The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. Clinical endocrinology. vol 68. issue 3. 2009-07-30. PMID:17941904. |
the clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. |
2009-07-30 |
2023-08-12 |
Not clear |
| Stine L Fougner, Olivera Casar Borota, Jens Petter Berg, John K Hald, Jon Ramm-Pettersen, Jens Bollersle. The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. Clinical endocrinology. vol 68. issue 3. 2009-07-30. PMID:17941904. |
reduced expression of the somatostatin receptor subtype 2 (sstr2) has been suggested as an explanation for the poor response to octreotide in acromegaly, but studies correlating levels of sstr2 mrna to octreotide efficacy have been contradictory. |
2009-07-30 |
2023-08-12 |
Not clear |
| N Karavitaki, H E Turner, C B T Adams, S Cudlip, J V Byrne, V Fazal-Sanderson, S Rowlers, P J Trainer, J A H Was. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clinical endocrinology. vol 68. issue 6. 2009-07-23. PMID:18031313. |
previous retrospective studies have also suggested that surgical debulking of pituitary tumours causing acromegaly improves control by somatostatin analogues. |
2009-07-23 |
2023-08-12 |
Not clear |
| A Lania, G Mantovani, A Spad. Genetic abnormalities of somatostatin receptors in pituitary tumors. Molecular and cellular endocrinology. vol 286. issue 1-2. 2009-07-17. PMID:17913341. |
nevertheless, polymorphic variants in sst2 and sst5 genes seem to have a minor, if any, role in determining the different responsiveness to somatostatin analogs in patients with acromegaly. |
2009-07-17 |
2023-08-12 |
human |
| Anat Ben-Shlomo, Shlomo Melme. Somatostatin agonists for treatment of acromegaly. Molecular and cellular endocrinology. vol 286. issue 1-2. 2009-07-17. PMID:18191325. |
somatostatin agonists for treatment of acromegaly. |
2009-07-17 |
2023-08-12 |
Not clear |
| Anat Ben-Shlomo, Shlomo Melme. Somatostatin agonists for treatment of acromegaly. Molecular and cellular endocrinology. vol 286. issue 1-2. 2009-07-17. PMID:18191325. |
the discovery of somatotropin-release inhibitory factor (srif) in hypothalamic extract in 1970 led to the synthesis of the first somatostatin analog octreotide, discovery of five somatostatin receptor subtypes, and development of additional somatostatin receptor ligands (srl) as pharmacotherapy for acromegaly and other neuroendocrine tumors. |
2009-07-17 |
2023-08-12 |
Not clear |
| Leonardo Vieira Neto, Evelyn de O Machado, Raul M Luque, Giselle F Taboada, Jorge B Marcondes, Leila M C Chimelli, Leonardo Pereira Quintella, Paulo Niemeyer, Denise P de Carvalho, Rhonda D Kineman, Mônica R Gadelh. Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly. The Journal of clinical endocrinology and metabolism. vol 94. issue 6. 2009-07-02. PMID:19293270. |
expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-lar in acromegaly. |
2009-07-02 |
2023-08-12 |
human |
| A A Nikolaeva, S V Koroleva, I P Ashmari. [Research of interactions in the dopamine-serotonin-somatostatin system promises new outlook in fundamental and practical respects]. Eksperimental'naia i klinicheskaia farmakologiia. vol 72. issue 2. 2009-06-22. PMID:19441733. |
potentially possible combinations of somatostatin and dopamine analogs, and chimeric somatostatin/dopamine molecules are proposed for the treatment and correction of different pathological states, including acromegaly, prolactinemia, and hyperinsulinism. |
2009-06-22 |
2023-08-12 |
Not clear |
| Gherardo Mazziotti, Irene Floriani, Stefania Bonadonna, Valter Torri, Philippe Chanson, Andrea Giustin. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. The Journal of clinical endocrinology and metabolism. vol 94. issue 5. 2009-05-28. PMID:19208728. |
effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. |
2009-05-28 |
2023-08-12 |
Not clear |
| M Sherlock, E Fernandez-Rodriguez, A Aragon Alonso, R C Reulen, J Ayuk, R N Clayton, G Holder, M C Sheppard, A Bates, P M Stewar. Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues. The Journal of clinical endocrinology and metabolism. vol 94. issue 4. 2009-05-14. PMID:19158203. |
medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues. |
2009-05-14 |
2023-08-12 |
Not clear |
| T D Filippatos, E N Liberopoulos, N Pavlidis, M S Elisaf, D P Mikhailidi. Effects of hormonal treatment on lipids in patients with cancer. Cancer treatment reviews. vol 35. issue 2. 2009-04-24. PMID:19013720. |
information regarding the effects on lipid profile of somatostatin analogues is available almost exclusively in patients with acromegaly. |
2009-04-24 |
2023-08-12 |
Not clear |
| S J C M M Neggers, W W de Herder, J A M J L Janssen, R A Feelders, A J van der Lel. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. European journal of endocrinology. vol 160. issue 4. 2009-04-16. PMID:19141604. |
combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. |
2009-04-16 |
2023-08-12 |
Not clear |
| S J C M M Neggers, W W de Herder, J A M J L Janssen, R A Feelders, A J van der Lel. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. European journal of endocrinology. vol 160. issue 4. 2009-04-16. PMID:19141604. |
we previously reported on the efficacy, safety, and quality of life (qol) of long-acting somatostatin analogs (ssa) and (twice) weekly pegvisomant (peg-v) in acromegaly and improvement after the addition of peg-v to long-acting ssa. |
2009-04-16 |
2023-08-12 |
Not clear |
| Ana Pokrajac, Jan Frystyk, Allan Flyvbjerg, Peter J Traine. Pituitary-independent effect of octreotide on IGF1 generation. European journal of endocrinology. vol 160. issue 4. 2009-04-16. PMID:19141605. |
somatostatin analogues are frequently used for medical treatment of acromegaly. |
2009-04-16 |
2023-08-12 |
Not clear |
| Mónica Marazuela, Tomás Lucas, Cristina Alvarez-Escolá, Manel Puig-Domingo, Nuria Garcia de la Torre, Paz de Miguel-Novoa, Alejandra Duran-Hervada, Rafael Manzanares, Manuel Luque-Ramírez, Irene Halperin, Felipe F Casanueva, Ignacio Bernabe. Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy. European journal of endocrinology. vol 160. issue 4. 2009-04-16. PMID:19147599. |
pegvisomant is an effective treatment for somatostatin analogue-resistant acromegaly, but the determinants defining the response to this treatment are largely unknown. |
2009-04-16 |
2023-08-12 |
Not clear |
| Annamaria Colao, Renata S Auriemma, Mariano Galdiero, Paolo Cappabianca, Luigi M Cavallo, Felice Esposito, Ludovica F S Grasso, Gaetano Lombardi, Rosario Pivonell. Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. The Journal of clinical endocrinology and metabolism. vol 94. issue 2. 2009-03-30. PMID:19001517. |
impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. |
2009-03-30 |
2023-08-12 |
Not clear |